Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease: Figure 1
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease: Figure 1
Authors
Keywords
-
Journal
BIOCHEMICAL SOCIETY TRANSACTIONS
Volume 42, Issue 2, Pages 600-604
Publisher
Portland Press Ltd.
Online
2014-03-20
DOI
10.1042/bst20140006
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: Effects of combined treatment and possible mechanisms of action
- (2013) Hanna Iderberg et al. EXPERIMENTAL NEUROLOGY
- AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study
- (2013) Fabrizio Stocchi et al. MOVEMENT DISORDERS
- NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
- (2013) Pierre Paoletti et al. NATURE REVIEWS NEUROSCIENCE
- Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
- (2012) M. A. Cenci et al. CNS & Neurological Disorders-Drug Targets
- Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease
- (2012) K. Elisabet Ohlin et al. NEUROIMAGE
- Synergy between l-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia
- (2012) Khaled-Ezaheir Bennouar et al. NEUROPHARMACOLOGY
- Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias
- (2011) Imtiaz Ahmed et al. BRAIN
- Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats
- (2011) Kristin B. Dupre et al. EXPERIMENTAL NEUROLOGY
- Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
- (2011) Christopher Kobylecki et al. MOVEMENT DISORDERS
- AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials
- (2011) Daniela Berg et al. MOVEMENT DISORDERS
- The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease
- (2011) Susan H. Fox et al. MOVEMENT DISORDERS
- In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels
- (2011) Flora Mela et al. NEUROBIOLOGY OF DISEASE
- The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in l-Dopa-treated parkinsonian monkeys
- (2011) Laurent Grégoire et al. PARKINSONISM & RELATED DISORDERS
- Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
- (2011) Véronique Sgambato-Faure et al. PROGRESS IN NEUROBIOLOGY
- Integrated Brain Circuits: Astrocytic Networks Modulate Neuronal Activity and Behavior
- (2010) Michael M. Halassa et al. Annual Review of Physiology
- Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson’s disease
- (2010) Christopher Kobylecki et al. JOURNAL OF NEUROCHEMISTRY
- Reduction of L-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease
- (2010) T. H. Johnston et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys
- (2010) Daniella Rylander et al. NEUROBIOLOGY OF DISEASE
- Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys
- (2010) Nicolas Morin et al. NEUROPHARMACOLOGY
- Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia
- (2010) S. Fasano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling
- (2009) D. Rylander et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Astrocytes and the regulation of cerebral blood flow
- (2009) Raymond C. Koehler et al. TRENDS IN NEUROSCIENCES
- Dissociation of Metabolic and Neurovascular Responses to Levodopa in the Treatment of Parkinson's Disease
- (2008) S. Hirano et al. JOURNAL OF NEUROSCIENCE
- Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism
- (2008) John G. Nutt et al. MOVEMENT DISORDERS
- l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation
- (2007) Barbara Picconi et al. NEUROBIOLOGY OF DISEASE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started